December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.97 -0.11 (-0.68%)
Streaming Delayed Price Updated: 3:16 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

News headline image
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗
 
Via Benzinga
News headline image
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26 ↗
CNBC The Aviation Sector Is Slammed By Sky-High Rents 
Via Benzinga
News headline image
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact ↗
 
Via Benzinga
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder ↗
 
Via Benzinga
News headline image
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried ↗
Shares hit their lowest point since November on the FDA's decision in HAE. 
Via Investor's Business Daily
News headline image
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Peering Into Takeda Pharmaceutical's Recent Short Interest ↗
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold... 
Via Benzinga
News headline image
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets ↗
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome... 
Via Benzinga
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could... 
Via FinancialNewsMedia
News headline image
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents ↗
 
Via Benzinga
News headline image
Peering Into Takeda Pharmaceutical's Recent Short Interest ↗
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which... 
Via Benzinga
News headline image
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful ↗
 
Via Benzinga
News headline image
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which... 
Via Benzinga
News headline image
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. 
Via Benzinga
News headline image
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
From Takeda Pharmaceutical Company Limited
Via Business Wire
As Health Problems Mount Patients Welcome New Treatments
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,... 
Via FinancialNewsMedia
News headline image
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act' ↗
Moderna tested a bivalent booster, which targets two Covid strains in one shot. 
Via Investor's Business Daily
News headline image
Quant Ratings Updated on 66 Stocks ↗
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10. 
Via InvestorPlace
News headline image
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
From Moderna, Inc.
Via AccessWire
News headline image
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
From Takeda Pharmaceutical Company Limited
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.